Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -30.8%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $42M | $40M | $498M | $779M | $908M | $1.1B | $1.6B | — | — | — | — |
| Enterprise Value | $-192266010 | $-194242959 | $240M | $613M | $805M | $647M | $1.3B | — | — | — | — |
| P/E Ratio → | -0.38 | — | 9.23 | — | — | — | 270.00 | — | — | — | — |
| P/S Ratio | 9.02 | 8.60 | 103.10 | 233.82 | 434.63 | 106.26 | 189.60 | — | — | — | — |
| P/B Ratio | 0.14 | 0.13 | 1.22 | 1.70 | 1.66 | 1.82 | 2.42 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -41.69 | 49.61 | 184.05 | 385.35 | 64.81 | 150.36 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 7.08 | — | — | 33.23 | 22.38 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 26.0% | -48.1% | -6546.2% | -1007.0% | 100.0% | -888.1% | -372.8% | -10828.5% | 64.6% |
| Operating Margin | -2114.7% | -2114.7% | -2818.9% | -4390.4% | -9464.4% | -1506.0% | -1433.1% | -1558.5% | -635.4% | -17756.9% | -1668.4% |
| Net Profit Margin | -2355.4% | -2355.4% | 1108.3% | -1972.9% | -2409.3% | -606.9% | 71.8% | 4847.4% | -266.7% | 4749.1% | -1101.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.8% | -30.8% | 12.4% | -13.1% | -8.9% | -9.8% | 0.9% | 103.0% | -37.8% | 39.5% | -38.0% |
| ROA | -19.3% | -19.3% | 8.3% | -9.4% | -6.1% | -6.3% | 0.6% | 60.9% | -11.2% | 9.7% | -15.6% |
| ROIC | -66.9% | -66.9% | -46.2% | -29.8% | -48.2% | -45.3% | -20.3% | -32.8% | -255.4% | -491.7% | -156.9% |
| ROCE | -18.8% | -18.8% | -22.6% | -23.4% | -29.8% | -19.7% | -14.8% | -27.7% | -86.0% | -143.7% | -56.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.05 | 0.06 | 0.09 | 0.09 | 0.12 | 0.06 | 0.07 | 0.12 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.77 | -0.63 | -0.36 | -0.19 | -0.71 | -0.50 | -0.14 | -0.63 | -1.02 | -0.61 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.42 | -1.42 | 3.37 | -1.23 | -50.04 | 4.13 | 19.02 | 117.29 | -4.60 | -6.85 | -11.22 |
Net cash position: cash ($254M) exceeds total debt ($20M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.59 | 6.59 | 9.33 | 6.76 | 3.99 | 2.22 | 2.29 | 1.21 | 0.98 | 0.72 | 1.41 |
| Quick Ratio | 6.59 | 6.59 | 9.33 | 6.76 | 3.99 | 2.10 | 2.29 | 1.21 | 0.98 | 0.73 | 1.42 |
| Cash Ratio | 6.02 | 6.02 | 8.87 | 6.37 | 3.61 | 2.06 | 2.23 | 1.17 | 0.94 | 0.69 | 1.38 |
| Asset Turnover | — | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.00 | 0.01 |
| Inventory Turnover | — | — | — | — | — | 3.95 | — | — | — | — | — |
| Days Sales Outstanding | — | 636.93 | 975.48 | 260.43 | 3904.45 | 131.27 | 128.61 | 97.76 | 29.61 | 1009.08 | 10.30 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | 0.0% | — | 0.3% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 10.8% | — | — | — | 0.4% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 4.9% | 5.1% | 21.6% | 2.5% | 2.9% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 4.9% | 5.1% | 21.6% | 2.5% | 2.9% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $2M | $27M | $28M | $28M | $29M | $29M | $29M | $27M | $24M | $23M |
Clinical trial binary outcomes
Based on reported figures, PureTech trades at a price-to-book ratio of 0.14, which suggests that the market significantly discounts the company's internal pipeline and platform technology relative to the liquid value of its equity holdings in founded entities and its substantial cash reserves.
The current valuation appears to reflect a persistent conglomerate discount, where investors struggle to assign a premium to the internal discovery engine. This pricing implies that the market views the company primarily as a holding vehicle rather than a high-growth therapeutic developer, warranting further investigation into whether the upcoming clinical readouts can catalyze a re-rating.
According to recent SEC filings, PureTech's ROIC has remained consistently negative, reaching -37.9% in 2025Q4, which highlights the structural challenge of compounding returns while the company remains in a high-burn, clinical-stage discovery phase without commercial product revenue to offset development costs.
The negative ROIC trend suggests that capital is being consumed to build intellectual property rather than to generate immediate returns. Investors should monitor whether the transition toward wholly-owned assets can eventually improve capital efficiency, as the current figures reflect the heavy upfront investment required for lymphatic and oral delivery platforms.
As reported in financial statements, PureTech's asset turnover remains extremely low at 0.01, reflecting a business model that is not designed for high-volume asset utilization but rather for the long-term development of specialized therapeutic intellectual property within its hub-and-spoke architecture.
The high DSO figures, which reached 258 days in 2025Q4, appear to be a byproduct of milestone-based revenue recognition rather than operational inefficiency in collecting receivables. This suggests that traditional working capital metrics are less indicative of operational health and more reflective of the lumpy, event-driven nature of biotech partnership accounting.
Based on reported figures, PureTech maintains a strong liquidity position with a current ratio of 6.59 as of 2025Q4, providing a significant buffer that mitigates the risk of immediate dilution while the company funds its internal pipeline through its substantial cash reserves.
The company's ability to maintain such high liquidity despite consistent negative free cash flow suggests a disciplined approach to capital preservation. This defensive posture appears to provide management with the necessary flexibility to navigate clinical trial volatility without the immediate pressure to access dilutive equity markets.
As evidenced by historical data, the most commonly misapplied metric for PureTech is the net profit margin, which frequently obscures the company's true economic performance by including non-recurring gains from equity exits that do not reflect the underlying operational health of the therapeutic discovery platform.
Investors should instead focus on cash burn and NAV-based valuation, as net income is heavily distorted by the accounting treatment of founded entities. Relying on traditional profitability ratios may lead to an inaccurate assessment of the company's ability to sustain its R&D programs, as these figures do not account for the optionality inherent in the Glyph technology platform.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRTC stock.
PureTech Health plc's current P/E ratio is -0.4x. The historical average is 9.2x.
PureTech Health plc's return on equity (ROE) is -30.8%. The historical average is -6.3%.
Based on historical data, PureTech Health plc is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.
PureTech Health plc has 100.0% gross margin and -2114.7% operating margin.